Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A major lung cancer trial showed promise but missed its mark. The phase 3 IMpower030 trial found that adding atezolizumab to chemotherapy more than doubled median event-free survival (62.8 vs. 34.9 months) in resectable NSCLC patients — but the results didn't reach statistical significance. The trial missed its primary endpoint, leaving the role of perioperative atezolizumab in this setting still under evaluation.
The phase 3 IMpower030 trial tested perioperative atezolizumab plus platinum-based chemotherapy against placebo in 440 patients with resectable stage IIB to IIIB non-small cell lung cancer (NSCLC). After a median follow-up of nearly 6 years, the atezolizumab arm showed more than double the median event-free survival — but the difference didn't reach statistical significance (P = .07), meaning the trial missed its primary endpoint.
Despite the miss, secondary outcomes painted a more encouraging picture. Pathological complete response rates were substantially higher in the atezolizumab group, and disease-free survival also favored the experimental arm. Researchers suggest that patient selection and sample size may have contributed to the outcome.
Why it matters: Even without a statistically significant win, these long-term data add to the growing body of evidence supporting perioperative immunotherapy in resectable NSCLC — a space where treatment options continue to evolve.
